Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma

American Journal of Dermatopathology

Volumn 32, Issue 8, 2010, Pages 809-814

  Abdou, Asmaa Gaber ^a   Hammam, Mostafa A ^a   Farargy, Shawky El ^a   Farag, Azza G A ^a   El Shafey, Eman Nabil ^a   Farouk, Sherine ^a   Elnaidany, Nada Farag ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b October University for Modern Sciences and Arts   (Egypt)

Author keywords

diagnosis; galectin 3; HMB 45; melanoma; prognosis

Indexed keywords

GALECTIN 3; HOMATROPINE METHYL BROMIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; EGYPT; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TROPANES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78650368407     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181e02f29     Document Type: Article

References (30)

1. El-Bolkainy MN, Nouh MA, El-Bolkainy TN. Skin Tumors (Malignant Melanoma) in Topographic Pathology of Cancer. 3rd edn. Egypt: National Cancer Institute, Cairo University; 2005:128-131.
2. Mokhtar N, Gouda I, Adel I. Malignant skin tumors. In: Mokhtar N, Gouda I, Adel I, eds. Cancer Pathology Registry, 2003-2004 and Time Trend Analysis. Cairo: NCI, El Sheraa Press; 2007:83-85.
3. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531.
4. Kashani-Sabet M, Rangel J, Torabian S, et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA. 2009;14:6268-6272.
5. Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007;22:621-628.
6. Chun-sheng C, Wei-guo D, He-sheng L, et al. Expression of galectin-3 in gastric carcinoma and its significance. Chinese J Cancer Res. 2004;3: 176-181.
7. Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005;25:3117-3121.
8. Matsuda Y, Yamagiwa Y, Fukushima K, et al. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res. 2008;38:1098-1111.
9. Kim SJ, Lee SJ, Sung HJ, et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008;120:211-216.
10. Khan MS, Dodson AR, Heatley MK. Ki-67, oestrogen receptor, and progesterone receptor proteins in the human rete ovarii and in endometriosis. J Clin Pathol. 1999;52:517-520.
11. Achilles E, Schroder S. Positive cytokeratin results in malignant melanoma. Pitfall in differential immunohistological diagnosis of occult neoplasms. Pathologe. 1994;15:235-241.
12. Pagès C, Rochaix P, al Saati T, et al. KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39:1136-1142.
13. Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008;35(s2):1-10.
14. Kapur RP, Bigler SA, Skelly M, et al. Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes. J Histochem Cytochem. 1992;40: 207-212.
15. Kucher C, Zhang PJ, Pasha T, et al. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol. 2004;26:452-457.
16. Fullen DR, Reed JA, Finnerty B, et al. S100A6 preferentially labels type C nevus cells and nevic corpuscles: additional support for Schwannian differentiation of intradermal nevi. J Cutan Pathol. 2001;28:393-399.
17. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
18. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 2002;118:930-936.
19. Kikuchi A, Shimizu H, Nishikawa T. Expression and ultrastructural localization of HMB-45 antigen. Br J Dermatol. 1996;135:400-405.
20. Xu X, Chu AY, Pasha TL, et al. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26:82-87.
21. Yu CH, Chen HH, Liu CM, et al. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. J Oral Pathol Med. 2005;34: 540-545.
22. Roy S, Dhingra K, Mandal S, Khurana N. Unusual presentation of metastatic amelanotic melanoma of unknown primary origin as a solitary breast lump. Melanoma Res. 2008;18:447-450.
23. Hubert M, Wang SY, Wang JL, et al. Intranuclear distribution of galectin-3 in mouse 3T3 fibroblasts: comparative analyses by immunofluorescence and immunoelectron microscopy. Exp Cell Res. 1995;220:397-406.
24. Prieto VG, Mourad-Zeidan AA, Melnikova V, et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006;12:6709-6715.
25. Lotz MM, Andrews CW Jr, Korzelius CA, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 1993;90:3466-3470.
26. Honjo Y, Inohara H, Akahani S, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6: 4635-4640.
27. Kapucuoglu N, Basak PY, Bircan S, et al. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract. 2009;205: 97-103.
28. Vereecken P, Debray C, Petein M, et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res. 2005;296:353-358.
29. Vereecken P, Heenen M. Serum galectin-3 in advanced melanoma patients: a hypothesis on a possible role in melanoma progression and inflammation. J Int Med Res. 2006;34:119-120.
30. Iacobini C, Amadio L, Oddi G, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S264-S270.